H&H国际控股：25年业绩反弹，修复动力具备持续性-20260401

Investment Rating - The report assigns a "Buy" rating to H&H International Holdings (1112.HK) [1] Core Insights - The company achieved a revenue of HKD 14.354 billion for FY25, representing a year-on-year increase of 10.0%, and a net profit of HKD 196 million, a significant increase of 465.2% year-on-year [2] - The adjusted comparable net profit for FY25 was HKD 664 million, up 22.7% year-on-year, with a proposed annual dividend of HKD 0.35 per share, accounting for approximately 30.0% of the adjusted comparable net profit [2] - The company is expected to maintain growth momentum in the nutritional supplement sector while stabilizing profit levels [10] Summary by Sections Revenue and Profitability - For FY25, the company's revenue from nutritional supplements, infant formula, and other income was HKD 9.289 billion, HKD 4.216 billion, and HKD 849 million, respectively, with year-on-year changes of +5.2%, +26.5%, and -4.5% [3] - The adjusted comparable net profit margin for FY25 was 4.6%, an increase of 0.5 percentage points year-on-year [7] Business Segments - The revenue breakdown by business segment for FY25 was as follows: ANC (HKD 6.946 billion, +3.7%), BNC (HKD 5.257 billion, +20.0%), and PNC (HKD 2.150 billion, +9.0%) [4] - The ANC segment's revenue from Swisse reached a milestone of HKD 1 billion, with double-digit growth in both the Chinese and Australian VHMS markets [4] Geographic Performance - Revenue from mainland China, North America, Australia/New Zealand, and other regions for FY25 was HKD 10.202 billion, HKD 1.748 billion, HKD 1.574 billion, and HKD 830 million, with year-on-year changes of +17.5%, +7.8%, -21.8%, and +7.8% respectively [5] - The mainland China market's contribution to total revenue increased from 66.6% to 71.1% [5] Supply Chain and Cost Management - The gross profit margin for FY25 was 62.4%, an increase of 1.8 percentage points year-on-year, driven by improvements in the gross margins of ANC and PNC segments [6] - The sales expense ratio for FY25 was 42.2%, reflecting a 0.9 percentage point increase year-on-year due to strategic investments in new markets [6] Financial Health - As of the end of FY25, the company had a cash balance of HKD 1.7 billion and reduced total liabilities by over HKD 600 million, with a net leverage ratio improved to 3.45 times [9] - The company plans to enhance its debt profile by increasing the proportion of low-cost RMB debt and reducing foreign exchange volatility [9] Future Outlook - Revenue forecasts for FY26 and FY27 have been adjusted to HKD 15.71 billion and HKD 17.19 billion, respectively, with an expected net profit of HKD 654 million and HKD 817 million [10] - The company aims to consolidate its position in the ANC segment in China, expand its market presence, and focus on high-margin nutritional products [9]